BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19846931)

  • 1. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.
    Martelli L; Ragazzi E; Di Mario F; Basato M; Martelli M
    Anticancer Res; 2009 Oct; 29(10):3931-7. PubMed ID: 19846931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
    Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
    Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
    Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
    Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
    Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
    Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the anti-proliferative effects of novel DNA-intercalating bipyridyl-thiourea-Pt(II) complexes against cisplatin-sensitive and -resistant human ovarian cancer cells.
    Marverti G; Cusumano M; Ligabue A; Di Pietro ML; Vainiglia PA; Ferrari A; Bergomi M; Moruzzi MS; Frassineti C
    J Inorg Biochem; 2008 Apr; 102(4):699-712. PubMed ID: 18082268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
    Fink D; Zheng H; Nebel S; Norris PS; Aebi S; Lin TP; Nehmé A; Christen RD; Haas M; MacLeod CL; Howell SB
    Cancer Res; 1997 May; 57(10):1841-5. PubMed ID: 9157971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
    Holzer AK; Manorek GH; Howell SB
    Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cytotoxicities of platinum compounds.
    Goodisman J; Hagrman D; Tacka KA; Souid AK
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin.
    Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM
    Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
    Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
    Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
    Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 41 degrees C and 43 degrees C on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin.
    Bergs JW; Haveman J; Ten Cate R; Medema JP; Franken NA; Van Bree C
    Oncol Rep; 2007 Jul; 18(1):219-26. PubMed ID: 17549371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation.
    Cemazar M; Pipan Z; Grabner S; Bukovec N; Sersa G
    Anticancer Res; 2006; 26(3A):1997-2002. PubMed ID: 16827135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.